Uncategorized
Genentech receives FDA breakthrough therapy designation for Lucentis
The U.S. Food and Drug Administration has granted breakthrough therapy designation for Lucentis for treatment of diabetic retinopathy, according to an announcement from Genentech.Previously, the FDA accepted the supplemental biologics license application and granted priority review status for the drug, the announcement said.Approval of Lucentis (ranibizumab) for treatment of diabetic retinopathy would be the fourth indication approved for the drug since 2006, the announcement said.